Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Long Term Follow up Study for Patients With Melanoma Who Were Previously Enrolled in the Phase I Study IMM-101-001

NCT01559818 is registered in ClinicalTrials.gov with Immodulon Therapeutics Ltd as lead sponsor.

NCT NCT01559818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01559818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Long Term Follow up Study for Patients With Melanoma Who Were Previously Enrolled in the Phase I Study IMM-101-001
Lead sponsor
Immodulon Therapeutics Ltd
Phase
Phase 1/2
Overall status
Terminated
Start date
February 29, 2012
Completion date
July 31, 2019
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma